

Balance Sheet

as at March 31, 2024

₹ in Million			
Particulars	Notes	As at March 31, 2024	As at March 31, 2023
ASSETS			
(1) Non-current assets			
(a) Property, plant and equipment	3A (I) & (II)	131,923.2	133,903.8
(b) Building	3D	31,077.3	29,633.5
(c) Goodwill	47	85,989.5	83,580.3
(d) Patents for drugs and formulations	3B	33,201.1	33,170.3
(e) Investment in Properties	3E	14,461.5	10,098.1
(f) Investment in associates	4	4,061.3	3,474.8
(g) Investment in joint venture	5	364.8	361.6
(h) Financial assets			
(i) Investments	6	59,986.2	50,680.9
(ii) Loans	7	8.5	6.1
(iii) Other financial assets	8	1,179.5	1,710.4
(i) Deferred tax assets (Net)	50	41,036.5	35,189.2
(j) Income tax assets (Net)	9	22,850.3	23,069.8
(k) Other non-current assets	10	4,739.3	3,723.7
Total non-current assets		419,879.0	408,602.5
(2) Current assets			
(a) Inventories	11	98,682.9	105,130.5
(b) Financial assets			
(i) Investments	12	85,845.4	93,726.1
(ii) Trade receivables	13	112,493.7	114,385.1
(iii) Cash and cash equivalents	14	92,856.5	46,237.3
(iv) Bank balances other than (iii) above	15	12,350.3	11,465.6
(v) Loans	16	650.2	413.2
(vi) Other financial assets	17	9,172.0	7,645.1
(c) Other current assets	18	22,280.1	19,616.5
Total current assets		434,331.1	398,619.4
Assets classified as held for sale	3C	418.7	214.0
TOTAL ASSETS		865,628.8	807,435.9

Balance Sheet

as at March 31, 2024

₹ in Million

Particulars	Notes	As at March 31, 2024	As at March 31, 2023
EQUITY AND LIABILITIES			
Equity			
(a) Equity share capital	19	2,399.3	2,399.3
(b) Other equity	20	634,268.2	557,554.5
Equity attributable to the equity shareholders of the parent company		636,667.5	559,953.8
Non-controlling interests	71	34,392.2	33,200.9
Total equity		671,059.7	593,154.7
Liabilities			
(1) Non-current liabilities			
(a) Financial liabilities			
(i) Borrowings	21	13.3	-
(ii) Lease liabilities	54	3,022.9	5,599.1
(iii) Other financial liabilities	22	-	37.9
(b) Provisions	23	4,138.9	3,429.1
(c) Deferred tax liabilities (Net)	50	1,550.6	316.9
(d) Other non-current liabilities	24	4,999.4	5,828.2
Total non-current liabilities		13,725.1	15,211.2
(2) Current liabilities			
(a) Financial liabilities			
(i) Borrowings	25	39,443.6	61,978.8
(ii) Lease liabilities	54	1,256.9	1,280.8
(iii) Trade payables	74	56,533.0	56,815.2
(iv) Other financial liabilities	26	15,067.0	15,930.9
(b) Other current liabilities	27	10,844.6	6,427.2
(c) Provisions	28	53,575.6	53,543.8
(d) Current tax liabilities (Net)	29	4,117.0	3,087.1
Total current liabilities		169,837.7	199,063.8
Liabilities directly associated with assets classified as held for sale	3C	6.3	6.2
Total liabilities		194,569.1	214,281.2
TOTAL EQUITY AND LIABILITIES		865,628.8	807,435.9

The accompanying notes are an integral part of the financial statements.
As per our report of even date

For **N B S B C & CO LLP**

Chartered Accountants

ICAI Firm Registration No.: 326482E/E346863

per **POUL ALWARES**

Partner

Membership No.: 1054

Mumbai, May 22, 2024

ARUP PANDEY

Company Secretary and Compliance Officer

For and on behalf of the Board of Directors of

MOON PHARMACEUTICAL INDUSTRIES LIMITED

ARJUN VINOD

Chairman and Managing Director

(DIN: 00004459)

RAMESH JAIN

Whole-time Director

(DIN: 01762734)

RAHUL RAMESH

Chief Financial Officer

Mumbai, May 22, 2024

Statement of Profit and Loss

for the year ended March 31, 2024

₹ in Million

Particulars	Notes	Year ended March 31, 2024	Year ended March 31, 2023
(I) Revenue from operations	30	484,968.5	438,856.8
(II) Other income	31	13,541.9	6,345.2
(III) Total income (I+II)		498,510.4	445,202.0
(IV) Expenses			
Cost of materials consumed	32	69,043.3	77,775.7
Purchases of stock-in-trade		144,661.5	135,715.0
Changes in inventories of finished goods, stock-in-trade and work-in-progress	33	2,921.3	(6,869.1)
Employee benefits expense	34	94,290.6	82,960.3
Finance costs	35	2,384.7	1,720.0
Depreciation and amortisation expense	3 (A & B)	25,566.4	25,294.3
R&D expenses	36	64,461.5	60,098.1
Other expenses		43,820.5	32,807.0
Total expenses (IV)		447,149.8	409,501.3
(V) Profit before exceptional items and tax (III-IV)		51,360.6	35,700.7
(VI) Exceptional items	61	4,943.2	1,714.5
(VII) Profit before tax (V-VI)		46,417.4	33,986.2
(VIII) Tax expense/(credit)			
Current tax		19,893.0	18,692.2
Deferred tax		(5,498.5)	(10,216.3)
Total tax expense (VIII)	49	14,394.5	8,475.9
(IX) Profit for the year before share of profit/(loss) of associates and joint venture (VII-VIII)		32,022.9	25,510.3
(X) Share of profit/(loss) of associates (net of tax)		(382.7)	(476.7)
(XI) Share of profit/(loss) of joint venture (net of tax)		(1.4)	(2.3)
(XII) Profit for the year before non-controlling interests (IX+X+XI)		31,638.8	25,031.3
(XIII) Non-controlling interests	71	336.5	393.6
(XIV) Profit for the year (XII-XIII)		31,302.3	24,637.7
Earnings per equity share (face value per equity share - ₹ 1)			
Basic		11.8	8.3
Diluted		11.8	8.3

The accompanying notes are an integral part of the financial statements.
As per our report of even date

For **N B S B C & CO LLP**
Chartered Accountants
ICAI Firm Registration No.: 326482E/E346863

per **POUL ALWARES**
Partner
Membership No.: 1054
Mumbai, May 22, 2024

ARUP PANDEY
Company Secretary and Compliance Officer

For and on behalf of the Board of Directors of
MOON PHARMACEUTICAL INDUSTRIES LIMITED

ARJUN VINOD
Chairman and Managing Director
(DIN: 00004459)

RAMESH JAIN
Whole-time Director
(DIN: 01762734)

RAHUL RAMESH
Chief Financial Officer
Mumbai, May 22, 2024

NOTE: 36 R&D Expenses

This fiscal year, our R&D expenses totalled ₹64,461.5 million, compared to ₹60,098.1 million in the previous year, reflecting an increase of approximately 7.3%.

Rationale for Expensing:

- R&D expenses are charged directly to the income statement as they are incurred, based on our accounting policy that aligns with the immediate recognition principle under applicable financial reporting standards. This approach is adopted because:
 - **Uncertainty of Future Benefits:** Unlike capitalizable R&D projects, these expenses relate to exploratory and early-stage research where the future economic benefits are highly uncertain and thus do not meet our criteria for capitalization.
 - **Immediate Recognition:** Expensing these costs immediately reflects a conservative approach to financial reporting, ensuring that our financial results are not overly influenced by speculative future benefits.

Below is a table that details the breakdown of R&D expenses for the fiscal year 2023-24, showcasing the diversity of projects and their respective financial commitments: -

Category	Amount (₹ in million)	Percentage of Total R&D Expenses	Description
New Drug Development	24,300.00	37.7%	Development of new pharmacological treatments for oncology.
Advanced Diagnostic Technologies	12,150.5	18.8%	Research in imaging technologies and personalized diagnostics.
Clinical Trials (Phase 3)	9,620.0	14.9%	Final stage clinical trials for new treatments.
Biotechnology Innovations	8,090.5	12.5%	Projects focussed on genetic research and biotech therapies.
Early-stage Pharmaceutical Research	4,550.3	7.1%	Exploratory research in new chemical entities.
Technology Upgrades for R&D Facilities	3,240.2	5.0%	Upgrades to R&D infrastructure to support advanced research.
Regulatory Compliance and Patents	2,610.0	4.0%	Costs associated with securing patents and regulatory approvals.
Total R&D Expenses	64,461.5	100%	Overall expenditure in R&D for fiscal year 2023-24.

Impact on Financial Performance:

- The expensing of R&D is a significant component of our operational costs but is critical to maintaining our competitive edge through continuous innovation. This year's increased investment reflects intensified efforts in areas such as autoimmune diseases and precision medicine.
- Despite the substantial outlay, these investments are crucial for pioneering new treatments and technologies that can drive future revenue streams and enhance market positioning.
- Scope of Research Activities: The expenditures cover a range of activities from basic research to advanced pre-clinical trials, focusing on areas where substantial unmet medical needs exist.
- Strategic Importance: These activities are essential for keeping our product pipeline robust and responsive to fast-evolving healthcare challenges.